Literature DB >> 27371726

Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Katherine A Waugh1, Sonia M Leach2, Brandon L Moore1, Tullia C Bruno1, Jonathan D Buhrman1, Jill E Slansky3.   

Abstract

Mechanisms of self-tolerance often result in CD8(+) tumor-infiltrating lymphocytes (TIL) with a hypofunctional phenotype incapable of tumor clearance. Using a transplantable colon carcinoma model, we found that CD8(+) T cells became tolerized in <24 h in an established tumor environment. To define the collective impact of pathways suppressing TIL function, we compared genome-wide mRNA expression of tumor-specific CD8(+) T cells from the tumor and periphery. Notably, gene expression induced during TIL hypofunction more closely resembled self-tolerance than viral exhaustion. Differential gene expression was refined to identify a core set of genes that defined hypofunctional TIL; these data comprise the first molecular profile of tumor-specific TIL that are naturally responding and represent a polyclonal repertoire. The molecular profile of TIL was further dissected to determine the extent of overlap and distinction between pathways that collectively restrict T cell functions. As suggested by the molecular profile of TIL, protein expression of inhibitory receptor LAG-3 was differentially regulated throughout prolonged late-G1/early-S phase of the cell cycle. Our data may accelerate efficient identification of combination therapies to boost anti-tumor function of TIL specifically against tumor cells.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27371726      PMCID: PMC4976021          DOI: 10.4049/jimmunol.1600589

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  92 in total

1.  Validating clustering for gene expression data.

Authors:  K Y Yeung; D R Haynor; W L Ruzzo
Journal:  Bioinformatics       Date:  2001-04       Impact factor: 6.937

2.  Differential gene expression detection using penalized linear regression models: the improved SAM statistics.

Authors:  Baolin Wu
Journal:  Bioinformatics       Date:  2004-12-14       Impact factor: 6.937

3.  E2F-1 functions in mice to promote apoptosis and suppress proliferation.

Authors:  S J Field; F Y Tsai; F Kuo; A M Zubiaga; W G Kaelin; D M Livingston; S H Orkin; M E Greenberg
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

Review 4.  The three main stumbling blocks for anticancer T cells.

Authors:  Lukas Baitsch; Silvia A Fuertes-Marraco; Amandine Legat; Christiane Meyer; Daniel E Speiser
Journal:  Trends Immunol       Date:  2012-03-23       Impact factor: 16.687

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

Review 7.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

8.  Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy.

Authors:  Melissa G Lechner; Saman S Karimi; Keegan Barry-Holson; Trevor E Angell; Katherine A Murphy; Connor H Church; John R Ohlfest; Peisheng Hu; Alan L Epstein
Journal:  J Immunother       Date:  2013 Nov-Dec       Impact factor: 4.456

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Tolerance of Tumor-Specific T cells in Melanoma Metastases.

Authors:  Katherine A Waugh; Sonia M Leach; Jill E Slansky
Journal:  J Clin Cell Immunol       Date:  2016-04-14
View more
  23 in total

Review 1.  Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections.

Authors:  Mary Philip; Andrea Schietinger
Journal:  Curr Opin Immunol       Date:  2019-06-08       Impact factor: 7.486

Review 2.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

3.  LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.

Authors:  Eunsil Sung; Minkyung Ko; Ju-Young Won; Yunju Jo; Eunyoung Park; Hyunjoo Kim; Eunji Choi; Ui-Jung Jung; Jaehyoung Jeon; Youngkwang Kim; Hyejin Ahn; Da-Som Choi; Seunghyun Choi; Youngeun Hong; Hyeyoung Park; Hanbyul Lee; Yong-Gyu Son; Kyeongsu Park; Jonghwa Won; Soo Jin Oh; Seonmin Lee; Kyu-Pyo Kim; Changhoon Yoo; Hyun Kyu Song; Hyung-Seung Jin; Jaeho Jung; Yoon Park
Journal:  Mol Ther       Date:  2022-05-06       Impact factor: 12.910

4.  Profiling of Protein O-GlcNAcylation in Murine CD8+ Effector- and Memory-like T Cells.

Authors:  Aime Lopez Aguilar; Yu Gao; Xiaomeng Hou; Gregoire Lauvau; John R Yates; Peng Wu
Journal:  ACS Chem Biol       Date:  2017-11-10       Impact factor: 4.634

5.  The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

Authors:  Jason B Williams; Brendan L Horton; Yan Zheng; Yukan Duan; Jonathan D Powell; Thomas F Gajewski
Journal:  J Exp Med       Date:  2017-01-23       Impact factor: 14.307

6.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Authors:  Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; John P Ray; Carl G de Boer; Russell W Jenkins; David J Lieb; Jonathan H Chen; Dennie T Frederick; Michal Barzily-Rokni; Samuel S Freeman; Alexandre Reuben; Paul J Hoover; Alexandra-Chloé Villani; Elena Ivanova; Andrew Portell; Patrick H Lizotte; Amir R Aref; Jean-Pierre Eliane; Marc R Hammond; Hans Vitzthum; Shauna M Blackmon; Bo Li; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Zachary A Cooper; Cloud P Paweletz; David A Barbie; Anat Stemmer-Rachamimov; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

7.  The T cell differentiation landscape is shaped by tumour mutations in lung cancer.

Authors:  Ehsan Ghorani; James L Reading; Jake Y Henry; Marc Robert de Massy; Rachel Rosenthal; Virginia Turati; Kroopa Joshi; Andrew J S Furness; Assma Ben Aissa; Sunil Kumar Saini; Sofie Ramskov; Andrew Georgiou; Mariana Werner Sunderland; Yien Ning Sophia Wong; Maria Vila De Mucha; William Day; Felipe Galvez-Cancino; Pablo D Becker; Imran Uddin; Theres Oakes; Mazlina Ismail; Tahel Ronel; Annemarie Woolston; Mariam Jamal-Hanjani; Selvaraju Veeriah; Nicolai J Birkbak; Gareth A Wilson; Kevin Litchfield; Lucia Conde; José Afonso Guerra-Assunção; Kevin Blighe; Dhruva Biswas; Roberto Salgado; Tom Lund; Maise Al Bakir; David A Moore; Crispin T Hiley; Sherene Loi; Yuxin Sun; Yinyin Yuan; Khalid AbdulJabbar; Samra Turajilic; Javier Herrero; Tariq Enver; Sine R Hadrup; Allan Hackshaw; Karl S Peggs; Nicholas McGranahan; Benny Chain; Charles Swanton; Sergio A Quezada
Journal:  Nat Cancer       Date:  2020-05-22

8.  Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.

Authors:  Pengcheng Wei; Kimberly R Jordan; Jonathan D Buhrman; Jun Lei; Hexiang Deng; Philippa Marrack; Shaodong Dai; John W Kappler; Jill E Slansky; Lei Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

9.  PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.

Authors:  Haiping Jiang; Haiqing Ni; Pan Zhang; Xiaoli Guo; Min Wu; Haoran Shen; Jie Wang; Weiwei Wu; Zhihai Wu; Jiazheng Ding; Rong Tang; Shuaixiang Zhou; Bingliang Chen; Michael Yu; Hua Jing; Junjian Liu
Journal:  Oncoimmunology       Date:  2021-06-24       Impact factor: 8.110

10.  Chromatin states define tumour-specific T cell dysfunction and reprogramming.

Authors:  Mary Philip; Lauren Fairchild; Liping Sun; Ellen L Horste; Steven Camara; Mojdeh Shakiba; Andrew C Scott; Agnes Viale; Peter Lauer; Taha Merghoub; Matthew D Hellmann; Jedd D Wolchok; Christina S Leslie; Andrea Schietinger
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.